Multimodality Treatment of Stage IIIA/N2 Non-Small Cell Lung Cancer: When YES to Surgery

2021 ◽  
Author(s):  
Sean All ◽  
David J. Sher
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Multimodality Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia

scholarly journals Multimodality Treatment of Stage IIIA and IIIB Non-small Cell Lung Cancer

2007 ◽  
Vol 2 (5) ◽  
pp. S35-S36 ◽  
Author(s):  
Wilfried Eberhardt ◽  
Thomas Gauler ◽  
Christoph Pöttgen ◽  
Thomas Krbek ◽  
Sönke Korfee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Multimodality Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia

Surgery as a Component of Multimodality Care for Known Stage IIIA-N2 Non-small Cell Lung Cancer

2020 ◽  
Vol 41 (03) ◽  
pp. 346-353 ◽  
Author(s):  
Adam J. Bograd ◽  
Eric Vallières
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Treatment Regimen ◽  
Cell Lung Cancer ◽  
Multimodality Treatment ◽  
Small Cell ◽  
Optimal Management ◽  
Small Cell Lung ◽  
Stage Iiia

AbstractLocally advanced, stage IIIA-N2 Non-small cell lung cancer (NSCLC) represents a heterogeneous patient population. Considerable controversy exists as to the optimal management of these patients. Local therapy alone with a single modality, namely surgery or radiation, is associated with high recurrence rates and low overall survival. Consequently, multimodality treatment (chemotherapy, radiotherapy, with or without the utilization of surgery) has developed as a means of both local and systemic control for patients with stage IIIA-N2 NSCLC, and has led to improved overall survival. While it is clear that multimodality therapy is beneficial, the ideal composition of the treatment regimen remains a work in progress. As a result, the optimal management of patients with stage IIIA-N2 NSCLC is widely debated, as is the role for surgery in a multimodality treatment regimen. Herein, we review the current literature supporting multimodality therapy for stage IIIA-N2 NSCLC with an emphasis on the data supporting the role of surgery in resectable and potentially resectable patients.

scholarly journals Incorporating Surgery in treatment of Stage IIIA – N2 Non- Small Cell Lung Cancer

2021 ◽  
Vol 5 (1) ◽  
pp. 33-43
Author(s):  
Binay Thakur ◽  
Mukti Devkota
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Multimodality Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Select Group ◽  
N2 Disease ◽  
Single Station

Stage IIIA-N2 Non-small cell lung cancer includes heterogenous group of patients with a poor 5-year survival ranging from 13% to 36% with surgery alone. Various randomized controlled trials established the role of multimodality treatment either including or excluding surgical resection. In a select group of non-bulky/ single station N2 disease, the better results have been achieved with induction chemotherapy or chemo-radiotherapy followed by surgery. 

scholarly journals Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non–Small-Cell Lung Cancer

2018 ◽  
Vol 14 (9) ◽  
pp. 569-571 ◽  
Author(s):  
Addie Hill ◽  
Jun Gong ◽  
Sharon Wilczynski ◽  
Rizvan Mirza ◽  
Loretta Erhunmwunsee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Pathologic Response ◽  
Complete Pathologic Response ◽  
Small Cell Lung ◽  
Stage Iiia
Sign in / Sign up

Export Citation Format

Share Document